^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HR20013

    i
    Other names: HR20013, HRS5580/palonosetron, HR 20013, HR-20013
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    NK-1 antagonist, Serotonin 3 receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    1m
    HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents (clinicaltrials.gov)
    P3, N=706, Completed, Fujian Shengdi Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    dexamethasone • HR20013
    5ms
    HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents (clinicaltrials.gov)
    P3, N=706, Active, not recruiting, Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    dexamethasone • HR20013
    1year
    HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents (clinicaltrials.gov)
    P3, N=700, Recruiting, Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2025 --> Sep 2025
    Enrollment open • Trial primary completion date
    |
    dexamethasone • HR20013
    over1year
    HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents (clinicaltrials.gov)
    P3, N=700, Not yet recruiting, Fujian Shengdi Pharmaceutical Co., Ltd.
    New P3 trial
    |
    dexamethasone • HR20013
    over2years
    Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P3, N=754, Active, not recruiting, Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HR20013 • dexamethasone injection • fosaprepitant